CN114901655A - 1-噻唑-2-基-吡唑-5-甲酸衍生物的结晶多晶型物 - Google Patents

1-噻唑-2-基-吡唑-5-甲酸衍生物的结晶多晶型物 Download PDF

Info

Publication number
CN114901655A
CN114901655A CN202080055654.8A CN202080055654A CN114901655A CN 114901655 A CN114901655 A CN 114901655A CN 202080055654 A CN202080055654 A CN 202080055654A CN 114901655 A CN114901655 A CN 114901655A
Authority
CN
China
Prior art keywords
crystalline polymorph
pyrazole
xrpd pattern
isopropylthio
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080055654.8A
Other languages
English (en)
Chinese (zh)
Inventor
A.库珀
Z.吴
S.邝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of CN114901655A publication Critical patent/CN114901655A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080055654.8A 2019-05-31 2020-05-29 1-噻唑-2-基-吡唑-5-甲酸衍生物的结晶多晶型物 Pending CN114901655A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855671P 2019-05-31 2019-05-31
US62/855,671 2019-05-31
PCT/US2020/035343 WO2020243584A1 (en) 2019-05-31 2020-05-29 Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative

Publications (1)

Publication Number Publication Date
CN114901655A true CN114901655A (zh) 2022-08-12

Family

ID=71787116

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055654.8A Pending CN114901655A (zh) 2019-05-31 2020-05-29 1-噻唑-2-基-吡唑-5-甲酸衍生物的结晶多晶型物

Country Status (7)

Country Link
US (1) US12378234B2 (https=)
EP (1) EP3976606A1 (https=)
JP (2) JP2022534429A (https=)
CN (1) CN114901655A (https=)
AU (2) AU2020283129A1 (https=)
CA (1) CA3142196A1 (https=)
WO (1) WO2020243584A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081983A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102453A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US12150934B2 (en) 2016-11-30 2024-11-26 Bantam Pharmaceutical, Llc Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102453A1 (en) * 2016-11-30 2018-06-07 Bantam Pharmaceutical, Llc Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张寿山主编: "《制药厂生产车间新技术新工艺流程与操作技能应用、质量控制设备运行维护实用全书 第1册》", vol. 1, 31 October 2005, 中国医药科技电子出版社, pages: 243 - 248 *

Also Published As

Publication number Publication date
CA3142196A1 (en) 2020-12-03
AU2026201586A1 (en) 2026-03-19
JP2022534429A (ja) 2022-07-29
US20220162204A1 (en) 2022-05-26
AU2020283129A1 (en) 2022-02-03
WO2020243584A1 (en) 2020-12-03
US12378234B2 (en) 2025-08-05
EP3976606A1 (en) 2022-04-06
JP2025160244A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
CN104185627B (zh) 吡啶酮衍生物
CN106029659B (zh) 谷氨酰胺酶抑制剂
CN105524048B (zh) 作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
KR102120883B1 (ko) 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR101829595B1 (ko) 3-（1-｛3-［5-（1-메틸-피페리딘-4일메톡시）-피리미딘-2-일］-벤질｝-6-옥소-1,6-디히드로-피리다진-3-일）-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법
CN106220644B (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN119490514A (zh) 一类作为小型gtp酶kras突变抑制剂的吡啶并嘧啶类衍生物
AU2017241524A1 (en) Pyrrolotriazine compounds as TAM inhibitors
WO2017167182A1 (zh) 一种选择性的c-kit激酶抑制剂
CN103930425A (zh) 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
WO2011075613A1 (en) Azaindole derivatives, their preparation and their therapeutic application
JP2017508779A (ja) ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−α］ピラジン誘導体および５，６，７，８−テトラヒドロ−４Ｈ−ピラゾロ［１，５−α］［１，４］ジアゼピン誘導体
KR20230019110A (ko) 4-아미노-5-(6-(4-메틸피페라진-1-일)-1H-벤조[D]이미다졸-2-일)티에노[2,3-b]피리딘-6(7H)-온(one)의 염 및 결정형
EA022434B1 (ru) Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент
WO2012031563A1 (zh) 杂环氨基小檗胺衍生物、其制备方法和应用
AU2026201586A1 (en) Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
JP2022538042A (ja) Ｃｄｋキナーゼ阻害剤
CN120302969A (zh) 可用作iap抑制剂的化合物和组合物
CN109988151B (zh) 一种炔类化合物、制备方法及其应用
CN116134022A (zh) Atr抑制剂和其用途
CN107304202A (zh) 五元杂环类化合物及其制备方法、药物组合物和用途
WO2020233716A1 (zh) 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
CN117105919A (zh) 一种靶向抗肿瘤药物及其在制备药物中的用途
KR101532850B1 (ko) 항암 활성을 갖는 벤즈아미드 유도체 및 이의 제조 방법 및 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination